Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 19500-19502 [2013-07446]
Download as PDF
<![CDATA[
19500
Federal Register / Vol. 78, No. 62 / Monday, April 1, 2013 / Notices
pmangrum on DSK3VPTVN1PROD with NOTICES
recommendations on molecular targets
within critical cellular toxicity
pathways in biochemical- or cell-based
assays or alternative animal models that
assess the potential ability of
compounds to act as toxicants to the
developing or adult nervous systems.
Request for Information
1. Information on technologies/assays
currently available for screening critical
pathways involved in neurotoxicity
where the endpoint is associated with a
phenotypic manifestation of toxicity in
vivo (adverse outcome).
a. The referred technologies/assays
should have the ability to batch screen
sets of at least 20 compounds to produce
a concentration response curve suitable
for defining the potency and efficacy of
a response and have been demonstrated
to be both reliable and relevant.
b. Specific information requested for
each assay includes the robustness of
the assay, dose-response and timecourse toxicity profiles, as well as to
what extent the assay informs on
specific neurotoxicity life-stage
windows (i.e., developmental, juvenile,
ageing).
2. Information on assays that can be
used to measure the activity of a
compound on a molecular initiating
event or key event within a
neurotoxicity adverse outcome pathway.
3. Information on the best molecular
or cellular targets that accurately
characterize the activity of a compound
within a specific pathway resulting in
an adverse neurotoxic outcome.
4. Information on assays,
technologies, or methods that will aid in
identifying neurotoxic compounds,
which are activated or deactivated by
metabolic activity.
Respondents to this RFI are asked to
provide the following: the Data
Universal Numbering System or DUNS®
number, organization name, address,
technical and administrative points of
contact (including names, titles,
addresses, telephone and fax numbers,
and email address), the North American
Industry Classification System (NAICS)
code, and size and type of business (e.g.,
8(a), HUBZone, WOSB, SDVOSB, etc.).
Information packages should not exceed
one (1) page in length, excluding
standard brochures. Telephone and
facsimile responses will not be
accepted. Electronic information should
be submitted in Microsoft Office (Word,
PowerPoint, Excel), Adobe PDF, or
compatible formats sufficient to clearly
read the information provided. Please
include a cover page identifying the
technical and administrative points of
contact for the organization, including
names, titles, addresses, telephone and
VerDate Mar<15>2010
15:34 Mar 29, 2013
Jkt 229001
fax numbers, email addresses, and
organization name. The deadline for
receipt of the requested information is
May 1, 2013.
Responses to this request are
voluntary. This notice does not obligate
the U.S. Government to award a contract
or otherwise pay for the information
provided in response to this request.
The U.S. Government reserves the right
to use information provided by
respondents for any purpose deemed
necessary and legally appropriate. Any
organization responding to this request
should ensure that its response is
complete and sufficiently detailed.
Respondents are advised that the U.S.
Government is under no obligation to
acknowledge receipt of the information
received or provide feedback to
respondents with respect to any
information submitted. No proprietary,
classified, confidential, or sensitive
information should be included in your
response.
Background Information on the NTP
The NTP is an interagency program
established in 1978 (43 FR 53060) to
coordinate toxicology research and
testing across the Department of Health
and Human Services. Other activities of
the program focus on strengthening the
science base in toxicology, developing
and validating improved testing
methods, and providing information
about potentially toxic chemicals to
health regulatory and research agencies,
scientific and medical communities,
and the public. Information about the
NTP is found at https://
ntp.niehs.nih.gov.
Dated: March 25, 2013.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2013–07420 Filed 3–29–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at
https://www.workplace.samhsa.gov and
https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires strict
standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
E:\FR\FM\01APN1.SGM
01APN1
Federal Register / Vol. 78, No. 62 / Monday, April 1, 2013 / Notices
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
pmangrum on DSK3VPTVN1PROD with NOTICES
Laboratories
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016, (Formerly:
Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150
Aegis Analytical Laboratories, 345
Hill Ave., Nashville, TN 37210, 615–
255–2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111
Newton St., Gretna, LA 70053, 504–
361–8989/800–433–3823, (Formerly:
Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA 23236,
804–378–9130, (Formerly: Kroll
Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll
Scientific Testing Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock, AR
72209–7056, 501–202–2783, (Formerly:
Forensic Toxicology Laboratory Baptist
Medical Center)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
ElSohly Laboratories, Inc., 5
Industrial Park Drive, Oxford, MS
38655, 662–236–2609
Fortes Laboratories, Inc., 25749 SW
Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503–486–1023
Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
VerDate Mar<15>2010
15:34 Mar 29, 2013
Jkt 229001
London, ONT, Canada N6A 1P4, 519–
679–1630
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919–
572–6900/800–833–3984, (Formerly:
LabCorp Occupational Testing Services,
Inc., CompuChem Laboratories, Inc.;
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street, Southaven,
MS 38671, 866–827–8042/800–233–
6339, (Formerly: LabCorp Occupational
Testing Services, Inc.; MedExpress/
National Laboratory Center)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS 66219,
913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.,)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR 97232,
503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology Laboratory,
1 Veterans Drive, Minneapolis, MN
55417, 612–725–2088
National Toxicology Laboratories,
Inc., 1100 California Ave., Bakersfield,
CA 93304, 661–322–4250/800–350–
3515
One Source Toxicology Laboratory,
Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888–747–3774, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7
Phamatech, Inc., 10151 Barnes
Canyon Road, San Diego, CA 92121,
858–643–5555
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432, (Formerly: SmithKline
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
19501
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370, (Formerly: SmithKline
Beecham Clinical Laboratories)
Redwood Toxicology Laboratory,
3650 Westwind Blvd., Santa Rosa, CA
95403, 707–570–4434
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend, IN
46601, 574–234–4176 x1276
Southwest Laboratories, 4625 E.
Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602–438–8507/800–
279–0027
STERLING Reference Laboratories,
2617 East L Street, Tacoma, Washington
98421, 800–442–0438
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–5235,
301–677–7085
*The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
E:\FR\FM\01APN1.SGM
01APN1
19502
Federal Register / Vol. 78, No. 62 / Monday, April 1, 2013 / Notices
the NLCP certification maintenance
program.
Janine Denis Cook,
Chemist, Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.
[FR Doc. 2013–07446 Filed 3–29–13; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[USCG–2013–0164]
Information Collection Requests to
Office of Management and Budget.
Coast Guard, DHS.
Sixty-day notice requesting
comments.
AGENCY:
pmangrum on DSK3VPTVN1PROD with NOTICES
ACTION:
SUMMARY: In compliance with the
Paperwork Reduction Act of 1995, the
U.S. Coast Guard intends to submit
Information Collection Requests (ICRs)
to the Office of Management and Budget
(OMB), Office of Information and
Regulatory Affairs (OIRA), requesting
approval of a revision to the following
collections of information: 1625–0049,
Waterfront Facilities Handling Liquefied
Natural Gas (LNG) and Liquefied
Hazardous Gas (LHG) and 1625–0063,
Marine Occupational Health and Safety
Standards for Benzene—46 CFR part
197 Subpart C. Our ICRs describe the
information we seek to collect from the
public. Before submitting these ICRs to
OIRA, the Coast Guard is inviting
comments as described below.
DATES: Comments must reach the Coast
Guard on or before May 31, 2013.
ADDRESSES: You may submit comments
identified by Coast Guard docket
number [USCG–2013–0164] to the
Docket Management Facility (DMF) at
the U.S. Department of Transportation
(DOT). To avoid duplicate submissions,
please use only one of the following
means:
(1) Online: https://
www.regulations.gov.
(2) Mail: DMF (M–30), DOT, West
Building Ground Floor, Room W12–140,
1200 New Jersey Avenue SE.,
Washington, DC 20590–0001.
(3) Hand delivery: Same as mail
address above, between 9 a.m. and 5
p.m., Monday through Friday, except
Federal holidays. The telephone number
is 202–366–9329.
(4) Fax: 202–493–2251. To ensure
your comments are received in a timely
manner, mark the fax, to attention Desk
Officer for the Coast Guard.
VerDate Mar<15>2010
15:34 Mar 29, 2013
Jkt 229001
The DMF maintains the public docket
for this Notice. Comments and material
received from the public, as well as
documents mentioned in this Notice as
being available in the docket, will
become part of the docket and will be
available for inspection or copying at
room W12–140 on the West Building
Ground Floor, 1200 New Jersey Avenue
SE., Washington, DC, between 9 a.m.
and 5 p.m., Monday through Friday,
except Federal holidays. You may also
find the docket on the Internet at
https://www.regulations.gov.
Copies of the ICRs are available
through the docket on the Internet at
https://www.regulations.gov.
Additionally, copies are available from:
COMMANDANT (CG–612), ATTN
PAPERWORK REDUCTION ACT
MANAGER, US COAST GUARD, 2100
2ND ST SW STOP 7101,
WASHINGTON DC 20593–7101.
FOR FURTHER INFORMATION CONTACT: Mr.
Anthony Smith, Office of Information
Management, telephone 202–475–3532,
or fax 202–475–3929, for questions on
these documents. Contact Ms. Renee V.
Wright, Program Manager, Docket
Operations, 202–366–9826, for
questions on the docket.
SUPPLEMENTARY INFORMATION:
Public participation and request for
comments.
This Notice relies on the authority of
the Paperwork Reduction Act of 1995;
44 U.S.C. Chapter 35, as amended. An
ICR is an application to OIRA seeking
the approval, extension, or renewal of a
Coast Guard collection of information
(Collection). The ICR contains
information describing the Collection’s
purpose, the Collection’s likely burden
on the affected public, an explanation of
the necessity of the Collection, and
other important information describing
the Collections. There is one ICR for
each Collection.
The Coast Guard invites comments on
whether these ICRs should be granted
based on the Collections being
necessary for the proper performance of
Departmental functions. In particular,
the Coast Guard would appreciate
comments addressing: (1) The practical
utility of the Collections; (2) the
accuracy of the estimated burden of the
Collections; (3) ways to enhance the
quality, utility, and clarity of
information subject to the Collections;
and (4) ways to minimize the burden of
the Collections on respondents,
including the use of automated
collection techniques or other forms of
information technology. In response to
your comments, we may revise these
ICRs or decide not to seek approval of
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
revisions of the Collections. We will
consider all comments and material
received during the comment period.
We encourage you to respond to this
request by submitting comments and
related materials. Comments must
contain the OMB Control Number of the
ICR and the docket number of this
request, [USCG–2013–0164], and must
be received by May 31, 2013. We will
post all comments received, without
change, to https://www.regulations.gov.
They will include any personal
information you provide. We have an
agreement with DOT to use their DMF.
Please see the ‘‘Privacy Act’’ paragraph
below.
Submitting comments
If you submit a comment, please
include the docket number [USCG–
2013–0164], indicate the specific
section of the document to which each
comment applies, providing a reason for
each comment. You may submit your
comments and material online (via
https://www.regulations.gov), by fax,
mail, or hand delivery, but please use
only one of these means. If you submit
a comment online via
www.regulations.gov, it will be
considered received by the Coast Guard
when you successfully transmit the
comment. If you fax, hand deliver, or
mail your comment, it will be
considered as having been received by
the Coast Guard when it is received at
the DMF. We recommend you include
your name, mailing address, an email
address, or other contact information in
the body of your document so that we
can contact you if we have questions
regarding your submission.
You may submit your comments and
material by electronic means, mail, fax,
or delivery to the DMF at the address
under ADDRESSES; but please submit
them by only one means. To submit
your comment online, go to https://
www.regulations.gov, and type ‘‘USCG–
2013–0164’’ in the ‘‘Keyword’’ box. If
you submit your comments by mail or
hand delivery, submit them in an
unbound format, no larger than 81⁄2; by
11 inches, suitable for copying and
electronic filing. If you submit
comments by mail and would like to
know that they reached the Facility,
please enclose a stamped, self-addressed
postcard or envelope. We will consider
all comments and material received
during the comment period and will
address them accordingly.
Viewing comments and documents:
To view comments, as well as
documents mentioned in this Notice as
being available in the docket, go to
https://www.regulations.gov, click on the
‘‘read comments’’ box, which will then
E:\FR\FM\01APN1.SGM
01APN1
]]>Agencies
[Federal Register Volume 78, Number 62 (Monday, April 1, 2013)]
[Notices]
[Pages 19500-19502]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07446]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories and Instrumented Initial Testing
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing
for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the Laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
A notice listing all currently certified Laboratories and
Instrumented Initial Testing Facilities (IITF) is published in the
Federal Register during the first week of each month. If any
Laboratory/IITF's certification is suspended or revoked, the
Laboratory/IITF will be omitted from subsequent lists until such time
as it is restored to full certification under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
developed in accordance with Executive Order 12564 and section 503 of
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace
Drug Testing Programs'', as amended in the revisions listed above,
requires strict standards that Laboratories and Instrumented Initial
Testing Facilities (IITF) must meet in order to conduct drug and
specimen validity tests on urine specimens for Federal agencies.
To become certified, an applicant Laboratory/IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a Laboratory/IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and Instrumented Initial Testing Facilities (IITF) in
the applicant stage of certification are not to be considered as
meeting the minimum requirements described in the HHS Mandatory
Guidelines. A Laboratory/
[[Page 19501]]
IITF must have its letter of certification from HHS/SAMHSA (formerly:
HHS/NIDA) which attests that it has met minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the minimum standards to conduct drug
and specimen validity tests on urine specimens:
Instrumented Initial Testing Facilities (IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY
14624, 585-429-2264
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101,
Memphis, TN 38118, 901-794-5770/888-290-1150
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210,
615-255-2400, (Formerly: Aegis Sciences Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-
361-8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little
Rock, AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802,
800-445-6917
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602,
229-671-2281
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044,
800-235-4890
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS
38655, 662-236-2609
Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503-486-1023
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT,
Canada N6A 1P4, 519-679-1630
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan,
NJ 08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa,
KS 66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.,)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN
55112, 651-636-7466/800-832-3244
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff,
Pasadena, TX 77504, 888-747-3774, (Formerly: University of Texas
Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology
Laboratory)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509-755-8991/800-541-7891x7
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121,
858-643-5555
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA
30084, 800-729-6432, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA
19403, 610-631-4600/877-642-2216, (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304, 818-737-6370, (Formerly: SmithKline Beecham Clinical
Laboratories)
Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA
95403, 707-570-4434
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x1276
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027
STERLING Reference Laboratories, 2617 East L Street, Tacoma,
Washington 98421, 800-442-0438
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson
St., Fort George G. Meade, MD 20755-5235, 301-677-7085
*The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 30, 2010 (75 FR 22809).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in
[[Page 19502]]
the NLCP certification maintenance program.
Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse
Prevention, SAMHSA.
[FR Doc. 2013-07446 Filed 3-29-13; 8:45 am]
BILLING CODE 4160-20-P
